Avidity Bio Crashes 26% After 'Rarer Than Rare' Event Sidelines Key StudyInvestors Business Daily • 03/30/23
Avidity's stock falls after sharing additional data about partial clinical holdMarket Watch • 03/30/23
Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific ConferencePRNewsWire • 03/13/23
Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent HighlightsPRNewsWire • 02/28/23
Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic LeaderPRNewsWire • 02/23/23
Avidity Biosciences Will Rise As It Revolutionizes The Field Of RNA TherapeuticsSeeking Alpha • 12/23/22
Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common StockPRNewsWire • 12/16/22
How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The StratosphereInvestors Business Daily • 12/14/22
Down 15.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Avidity Biosciences, Inc. (RNA)Zacks Investment Research • 11/18/22
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/22
Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent HighlightsPRNewsWire • 11/08/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avidity Biosciences, Inc. - RNANewsfile Corp • 10/08/22
Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle SocietyPRNewsWire • 10/06/22
SHAREHOLDER ALERT: Investigation of Avidity (RNA) Announced by Holzer & Holzer, LLCNewsfile Corp • 09/29/22
Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines StudyInvestors Business Daily • 09/27/22
Avidity shares fall 23% after announcing partial clinical hold for myotonic dystrophy trialMarket Watch • 09/27/22